Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
New Managers April 2013

EManagers DB Insights - Most EManagers' currency funds book profits in Q1-13

When a plethora of events happens simultaneously in the global economy, it is very hard to control your trading bets, especially, when you live in the age of quantitative easing.

But of the six funds trading in currency markets that are listed in Opalesque's Emanagers Database, four managed to make gains in first quarter of 2013.

Meanwhile, the Barclay CTA Currency Traders index was up 0.27% (est.) in March and up 1.31% YTD.

Among the six currency funds listed in the Emanagers database, compounded return in Q1 for the CTAs IStar Systematic Fund which follows a trend following strategy, and LNAM Diversified Forex, which applies spread arbitrage in its trading strategy, were up 3.01% and 3.93%, respectively. ROW Currency Fund, a global macro fund which incorporate active leverage investing in global currency markets, was up 4.61% and SHARPE+SIGNA Managed Currency Series (SMA), which specializes in systematic, technical and fundamental investment strategies in currencies, was up 5.87%. Meanwhile, Sherpa Funds' K2 Segregated Portfolio a CTA in global macro discretionary strategy, was down 0.66% and ......................

To view our full article please login

This article was published in Opalesque's New Managers a top-down monthly analysis, news and research publication on the global emerging manager space.
New Managers
New Managers
New Managers

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its